

PHENOTYPIC SCREENING OF CARBAPENEM RESISTANT
PSEUDOMONAS AERUGINOSA ISOLATES FROM BURN PATIENTS

Anees Ahmad

Department of Medical Lab Technology, Hazara University Mansehra Pakistan
aneesahmad884771@gmail.com

Jasia Abbasi

Department of Microbiology, Abbottabad University of Science & Technology
jasiaabbasi2@gmail.com

Yasir Ali

Peshawar Medical Collegue
yasirali8297734@gmail.com,

Khadija Mariyum

Department of Pharmacology, Peshawar Medical College
khadijamariyum@gmail.com

Eman Khan

Department of Medical Lab Technology, Hazara University Mansehra Pakistan
emankhanz023@gmail.com

Palwasha Imtiaz

Healt Care Center Johar Khatoon Hospital

Muhammad Ishaq

Department Pf Fprensic Medicine, Peshawar Medical College
ishaqm9545@gmail.com

Zahra Batool

Department of Medical Lab Technology, Abbottabad University of Science & Technology
zarabel2023@gmail.com

Mohsin Hanif

Department of Medical Lab Technology, Abbottabad University of Science & Technology
mohsin.hanif012@gmail.com

Syed Muzamil Shah

Department of Medical Lab Technology, Hazara University Mansehra Pakistan
muzammil77781@gmail.com

Farman Ali

Department of Microbiology, Abbottabad University of Science & Technology
farman.faryal@gmail.com

Muhammad Mehtab Ahmad Khan

Department of Microbiology, Abbottabad University of Science & Technology
mehtabahmadkhan1@gmail.com

Author Details**Keywords:**

Cardiovascular Disease,
Cardiovascular Risk Factors,
Cardiac Biomarker

Received on 03 Apr 2026

Accepted on 04 May 2026

Published on 30 May 2026

Corresponding E-mails &
Authors*:

Farman Ali

farman.faryal@gmail.com

Muhammad Mehtab Ahmad
Khan

mehtabahmadkhan1@gmail.com

Abstract

Pseudomonas aeruginosa is an opportunistic pathogen and causes variety of infections, including respiratory tract infections and skin associated infections. Antimicrobial resistance, mainly multidrug resistant *P. aeruginosa* (MDRPA), is a pressing concern related to *P. aeruginosa* infections. The present study aims at screening carbapenemase producing *P. aeruginosa* isolates from burn patients. Altogether 200 swab samples were collected from the burn and care unit of Pakistan Ordnance Factory (POF) hospital, Wah Cantt. Samples were processed for biochemical and microbiological identification. Antibiotic susceptibility testing was done by disc diffusion method. Carbapenemase detection was performed by carbapenem inactivation method (CIM). Overall, the results confirmed 80 (42%) of the isolates as *P. aeruginosa*, followed by *E. coli* (23.8%). *K. pneumoniae* and *S. aureus* (each 14.28%). The results also revealed that *P. aeruginosa* exhibited high susceptibility to levofloxacin (100%), while highest resistance was observed against meropenem (100%) followed by ciprofloxacin (50%), imipenem (50%) and gentamicin (45%). Further, CIM method revealed that 48 out of 80 (60%) of the isolates were positive for carbapenemase production. These findings underscore the varying susceptibility patterns of *P. aeruginosa* to different antibiotics commonly used in clinical practice. The results also highlight the notable presence of carbapenem resistant *P. aeruginosa* further endorsing the need of novel therapeutic drugs to treat such infections.

INTRODUCTION

Pseudomonas aeruginosa, primarily identified in 1882 by Gessard and recognized as a pathogen in 1890 by Charrin, has arose as a significant threat, particularly among susceptible populations such

as weakened, burned, cystic fibrosis, and immunocompromised individuals (1, 2). It is pervasive in numerous environmental positions including soil, water, plants, and animals. The bacterium is known for producing unique pigments, pyoverdine and pyocyanin, and produces a distinctive fruity odor due to the production of 2-aminoacetophenone(3-5). Colonies on sheep blood agar plates typically exhibit beta-hemolysis and a greenish metallic sheen. *P. aeruginosa* is non-fermentative, obligatory aerobic, and capable in making biofilms, which pose challenges in antimicrobial treatment due to their resistance to conventional treatments (4, 6).

In the last two decades, *P. aeruginosa* has arose as a significant pathogen, contributing to about 10-20% of infections within hospital settings. Mostly dominant among individuals with burn wounds, cystic fibrosis, acute leukemia, organ transplants, and intravenous drug use, *Pseudomonas* infections pose a significant risk (7). Frequently found as a nosocomial contaminant, outbreaks have been connected to various items in hospital settings. Prolonged hospital stays increase the probability of colonization by *P. aeruginosa*, increasing the risk of infection. Severe infections associated with this pathogen include malignant external otitis, endophthalmitis, endocarditis, meningitis, pneumonia, and septicemia (8).

Burn wounds are a major public health concern globally, often resulting in death or serious difficulties due to infection (9). The compromised skin barrier following burns allows for the entry of harmful microorganisms, with *P. aeruginosa* being a prominent cause of colonization and severe wound infections. Such colonization can escalate to sepsis, increasing morbidity and mortality rates among burn patients. Furthermore, the prevalence of multi-drug resistant strains poses extra tasks in managing these infections (10). The prevalence of *P. aeruginosa* infections in burn patients presents significant challenges in treatment and management. This bacterium is notorious for its intrinsic resistance to multiple antimicrobial agents and its ability to develop acquired resistance mechanisms rapidly. Moreover, *P. aeruginosa* can form biofilms on wound surfaces, further exacerbating treatment difficulties and increasing the risk of chronic infections.

P. aeruginosa is a ubiquitous Gram-negative bacterium known for its opportunistic pathogenicity, particularly in immunocompromised individuals and those with burn injuries. Burn wounds provide an ideal environment for *P. aeruginosa* colonization and infection due to compromised skin barriers and impaired immune responses. Burn patients are at heightened risk of *P. aeruginosa* infections, which can lead to severe complications and increased mortality rates. The prevalence of *P. aeruginosa* infections in burn patients presents significant challenges in treatment and management. This bacterium is notorious for its intrinsic resistance to multiple antimicrobial agents and its ability to develop acquired resistance mechanisms rapidly. Moreover, *P. aeruginosa* can form biofilms on wound surfaces, further exacerbating treatment difficulties and increasing the risk of chronic infections.

Empirical therapy for *P. aeruginosa* wound infections in burn patients often involves the use of broad-spectrum antibiotics, including carbapenems, due to their efficacy against Gram-negative bacteria. However, the rising prevalence of carbapenem-resistant *P. aeruginosa* strains poses a serious therapeutic challenge, necessitating alternative treatment approaches.

Understanding the epidemiology and antibiotic susceptibility patterns of *P. aeruginosa* infections in burn patients is essential for guiding appropriate therapeutic interventions and infection control measures. Surveillance studies play a crucial role in monitoring trends in antimicrobial resistance and informing empirical treatment protocols to optimize patient outcomes and minimize the spread of resistant strains within healthcare settings.

MATERIALS AND METHODS

Study Location and Sample Collection

This Cross-Sectional Laboratory-Based Observational Study was conducted at the Department of Microbiology, Hazara University, Mansehra. Clinical isolates were collected from Pakistan Ordnance Factory (POF) Hospital, Wah Cantt, Taxila. A total of 200 samples were obtained from hospitalized

burn patients, yielding 80 *P. aeruginosa* isolates. Ethical approval was secured from the POF Hospital Ethics Committee prior to sample collection.

Sample Processing

Following collection, the clinical samples were immediately transported to the Department of Microbiology, Hazara University, Mansehra, under aseptic conditions and processed within two hours of arrival. Each sample was cultured on general purpose, selective and differential media, including Nutrients Agar and MacConkey agar, and incubated at 37°C for 24 - 48 hours. Colonies showing characteristic morphology of *Pseudomonas aeruginosa* such as green pigmentation and grape-like odor were further subjected to Gram staining and standard biochemical tests (oxidase, catalase, citrate, indole, and coagulase) for preliminary identification. Isolates presumptively identified as *P. aeruginosa* were preserved on nutrient agar slants and stock culture were prepared and stored at 4°C for further antimicrobial susceptibility testing and phenotypic screening.

Stock culture preparation

P. aeruginosa was streaked onto MacConkey agar media, and the plates were incubated at 37 °C for 24 hours. Following incubation, optimum growth was observed on the agar plate. To prepare a stock culture, a loopful of bacterial growth was transferred from the MacConkey agar plate into a sterilized liquid broth. Subsequently, this liquid broth was incubated overnight at 37 °C. The next day, 15% glycerol was added to the bacterial culture, and it was stored in 400 µl aliquots at -20 °C for preservation.

Antimicrobial susceptibility testing.

Antimicrobial susceptibility testing (AST) was done to evaluate the response of *P. aeruginosa* isolates to six different antibiotics: tobramycin, gentamicin, levofloxacin, ciprofloxacin, imipenem, and meropenem. The selected methodology for this evaluation involved the commonly employed disc

diffusion method, offering a reliable and uniform approach. Bacterial isolates of *P. aeruginosa* were primarily subculture onto Mueller-Hinton agar (MHA) plates, followed by an incubation period at 37 °C for 18-24 hours. Then, a standardized bacterial suspension was prepared to achieve a specific turbidity in accordance with the McFarland standard. This suspension was then uniformly spread across the surface of Mueller-Hinton agar plates. Discs saturated with recognized concentrations of tobramycin, gentamicin, levofloxacin, ciprofloxacin, imipenem, and meropenem were aseptically placed on the inoculated agar plates. The plates were then incubated under standardized conditions, and after the incubation period, the diameter of the resulting inhibition zones around each antibiotic disc was accurately measured using a standardized ruler.

The recorded measurements were interpreted based on recognized interpretative standards provided by authoritative bodies such as the Clinical and Laboratory Standards Institute (CLSI) or the European Committee on Antimicrobial Susceptibility Testing (EUCAST). These standards categorized the isolates as susceptible, intermediate, or resistant, forming the basis for the determination of the strains' susceptibility profiles to the tested antibiotics.

Phenotypic screening of carbapenem-resistant *P. aeruginosa*.

The phenotypic screening of carbapenem-resistant *P. aeruginosa* was undertaken through the use of the Carbapenem Inactivation Method (CIM), a vital method for identifying carbapenemase production. The methodology involved some systematic steps. Initially, *P. aeruginosa* isolates were cultured and their identities confirmed (11). Then, a standardized bacterial suspension of *P. aeruginosa* was prepared, and imipenem and meropenem discs were immersed in the bacterial suspension, undergoing incubation at 37 °C for two hours. To check carbapenemase activity, a second step involved spreading *Escherichia coli* (ATCC 25922) on Mueller-Hinton agar plates, onto which the previously incubated discs were then placed. They were subsequently incubated at 37°C for 24 hours. The presence of a visible zone of growth inhibition around the carbapenem discs indicated susceptibility, while the absence of such inhibition strongly suggested the production of

carbapenemase. This sequential approach provided a robust method for confirming carbapenem resistance mechanisms in *P. aeruginosa* isolates.

RESULTS:

Isolation and Biochemical Identification of *Pseudomonas aeruginosa*

A total of 200 clinical samples were collected from burn patients for the isolation, antimicrobial susceptibility testing, and phenotypic screening of carbapenem-resistant *P. aeruginosa*. Of these, 168 samples (84%) yielded positive bacterial growth on selective media, while 32 samples (16%) showed no growth as shown in figure 1. Identification was confirmed through standard biochemical assays, revealing Gram-negative, rod-shaped bacteria that were catalase-positive, oxidase-positive, indole-negative, and coagulase-negative. These biochemical characteristics facilitated the accurate identification of *P. aeruginosa* and differentiation from other Gram-negative pathogens, aiding in effective clinical management and infection control.




Figure 1: Distribution of positive and negative samples

Ahmad et al - 2026


3007-2387

3007-2379

DOI: <http://doi.org/10.5281/zenodo.20508991>



Gram-negative rod






Figure 2: The figures show Gram-negative rods, oxidase positive, indole negative and catalase positive results for *P. aeruginosa*.

Specie wise distribution of bacteria isolated from burn patients

In the current study, a comprehensive analysis of bacterial isolates from burn patients revealed the presence of both gram-positive and gram-negative bacteria. Gram-positive bacteria were identified as *Staphylococcus*, accounting for 14.28% of the total isolates. On the other hand, gram-negative bacteria comprised a diverse range of species, with *P. aeruginosa* being the most prevalent, constituting 47.61% of the isolates. *Escherichia coli* accounted for 23.8% of isolates, while *Klebsiella* species comprised 14.28% as shown in Figure 3. Species wise distribution of bacterial isolates from the given study underscores the predominance of *P. aeruginosa*, followed by *Escherichia coli*, in the bacterial flora of burn patients. *Staphylococcus* and *Klebsiella* species were also identified but in relatively lower proportions compared to *P. aeruginosa* and *Escherichia coli*. This detailed analysis provides valuable insights into the spectrum of bacterial pathogens colonizing burn wounds in the studied population.

Table 1: Distribution of species wise bacteria isolated from burn patients.

Isolated organisms	No. of positive Samples	Percentage
Pseudomonas aeruginosa	80	47.61%
Escherichia coli	40	23.8%
Staphylococcus	24	14.28%
Klebsiella spp.	24	14.28%




Figure 3: Specie wise distribution of bacteria isolated from burn patients.

Antibiotic susceptibility pattern of *P. aeruginosa*

In this study, the antibiotic sensitivity testing against *P. aeruginosa*, a common pathogen in burn patients, was conducted using six commonly used antibiotics: tobramycin, gentamicin, levofloxacin, ciprofloxacin, imipenem, and meropenem. The results, as depicted in Table 2, revealed variations in the zone of inhibition of bacterial growth among the different antibiotics tested, as well as within samples treated with the same antibiotic (Figure 3). Notably, *P. aeruginosa* exhibited high susceptibility to levofloxacin, with 100% sensitivity observed in the isolated strain. Conversely, the bacterium displayed the highest resistance to meropenem, with 100% of strains exhibiting resistance. Ciprofloxacin and gentamicin demonstrated moderate sensitivity, with 50% and 45% sensitivity, respectively. However, Imipenem exhibited 50% resistance in the tested strains. Ciprofloxacin and

Ahmad et al - 2026

3007-2387

3007-2379

DOI: <http://doi.org/10.5281/zenodo.20508991>

gentamicin displayed moderate sensitivity, with 50% and 45% sensitivity, respectively, while Imipenem exhibited 50% resistance. These findings underscore the varying susceptibility patterns of *P. aeruginosa* to different antibiotics commonly used in clinical practice.

Table 2. Antibiotic Susceptibility Pattern *P. aeruginosa*

	Antibiotics	Pseudomonas aeruginosa (n=20)		
		Sensitivity (%)	Intermediate Sensitivity (%)	Resistance (%)
1.	Tobramycin	35	35	30
2.	Ciprofloxacin	50	30	20
3.	Levofloxacin	100	0	0
4.	Gentamicin	45	30	25
5.	Imipenem	25	25	50
6.	Meropenem	0	0	100




Figure 4. The given figure illustrated antibiotic susceptibility pattern of *P. aeruginosa*. Notably, all isolated strains displayed 100% susceptibility to levofloxacin while exhibiting 100% resistance to meropenem, highlighting significant differences in susceptibility among commonly used antibiotics.




Figure 5. Zone of inhibition of different antibiotics to *P. aeruginosa* on MHA. The given picture illustrates antibiotic susceptibility pattern of *P. aeruginosa*. Notably, all isolated strains displayed 100% susceptibility to levofloxacin while exhibiting 100% resistance to meropenem, highlighting significant differences in susceptibility among commonly used antibiotics.

Frequency of carbapenemase producing *P. aeruginosa*

Our results give important insights into the frequency of carbapenem resistance among clinical isolates of *P. aeruginosa*. Out of the 80 isolates analyzed, 48(60%) samples shown zone is less than 5 mm in CIM experiment; mean they were positive for the presence of carbapenemase enzyme. This specifies the existence of carbapenemase-producing strains of *P. aeruginosa* within the given samples. The detection of carbapenemase enzyme in the majority of samples advises an important frequency of carbapenem resistance among *P. aeruginosa* isolates obtained from burn patients. This finding underlines the crucial need for heightened attentiveness and proactive measures to mitigate the spread of carbapenem-resistant *P. aeruginosa* in clinical settings.




Figure 6: The figures show positive and negative isolates *P. aeruginosa* for carbapenemase enzyme.

Discussion

Pseudomonas aeruginosa is a Gram-negative, opportunistic bacterium that commonly affects immunocompromised and burn patients, leading to serious infections such as those of the wounds, urinary tract, respiratory system, and bloodstream (6). Its strong adaptability, ability to form biofilms, and natural resistance to many antibiotics especially carbapenems make it difficult to treat and control in healthcare settings. The rise of multidrug-resistant strains has become a global health concern. Due to the high mortality rates, particularly in hospital-acquired infections, continuous regional monitoring is essential to understand resistance trends and support the selection of effective empirical therapies (12).

P. aeruginosa is frequently isolated from burn wounds, presenting challenges in treatment and control due to its prolonged survival in the environment and resistance to multiple antimicrobial agents (13). Burn patients, particularly those exposed to carbapenems and broad-spectrum

Ahmad et al - 2026

3007-2387

3007-2379

DOI: <http://doi.org/10.5281/zenodo.20508991>

antibiotics, are at higher risk of *P. aeruginosa* infections, exacerbated by extended hospital stays and prior antibiotic use. The prevalence of antibiotic resistance complicates empiric therapy for *P. aeruginosa* wound infections (13, 14). *P. aeruginosa* continues to be the primary pathogen responsible for wound infections in burn centers. Studies have consistently reported a high incidence of *P. aeruginosa* infections in these settings (15). Notably, the ICU records the highest frequency of *P. aeruginosa* cases, likely due to prolonged hospitalization and extensive antibiotic usage. Moreover, multi-drug resistance is prevalent among *P. aeruginosa* strains associated with burn wounds (16). Similarly, other studies such as Arslan et al (17) and Naqvi et al (18) Bhatt et al (19) also showed a prevalence of *P. aeruginosa* infection among burn patients to be 53.97%, 59.6% and (76.8%) respectively. However, Ekrami and Kalantar (20) showed a prevalence of 37.5%.

Similarly, other studies such as Bhatt et al. (19) reported that *P. aeruginosa* isolated from burn patients exhibited 61% resistance to imipenem and 54% resistance to meropenem. However, Moazami-Goudarzi and Eftekhar (21) observed that 94.7% of isolates were resistant to both imipenem and meropenem in their study. Saderi et al. (22) found that 69% of isolated *P. aeruginosa* strains were MDR, whereas Moazami-Goudarzi and Eftekhar (21) reported 100% MDR isolates in burn patients. The high resistance rates observed in *P. aeruginosa* against clinically relevant antibiotics underscore the urgent need for alternative treatment approaches. However, the efficacy of single agents may be compromised when used as monotherapy, necessitating combination therapy for optimal outcomes.

Our results give important insights into the frequency of carbapenem resistance among clinical isolates of *P. aeruginosa*. Out of the 80 isolates analyzed, 48 (60%) samples shown zone is less than 5 mm in CIM experiment; mean they were positive for the presence of carbapenemase enzyme. This specifies the existence of carbapenemase-producing strains of *P. aeruginosa* within the given samples. The detection of carbapenemase enzyme in the majority of samples advises an important frequency of carbapenem resistance among *P. aeruginosa* isolates obtained from burn patients. This finding

Ahmad et al - 2026

3007-2387

3007-2379

DOI: <http://doi.org/10.5281/zenodo.20508991>

underlines the crucial need for heightened attentiveness and proactive measures to mitigate the spread of carbapenem-resistant *P. aeruginosa* in clinical settings.

On the other hand, 8(40%) samples tested negative for carbapenemase enzyme. This advises the lack of carbapenemase-producing *P. aeruginosa* among these samples. However, it is important to understand these negative results with caution, as the absence of carbapenemase enzyme does not essentially specify susceptibility to carbapenems. Other mechanisms of carbapenem resistance, such as alterations in outer membrane permeability or efflux pump overexpression, could contribute to resistance in these strains. Further examination into the mechanisms of carbapenem resistance in these samples is warranted to better understand the dynamics of antibiotic resistance in *P. aeruginosa* isolates from burn patients.

Overall, the results of this study highlight the complex nature of antibiotic resistance in *P. aeruginosa* and underline the requirement for complete surveillance and infection control measures to address the tasks posed by carbapenem-resistant pathogens in clinical practice. Further research is necessary to explain the molecular mechanisms underlying carbapenem resistance in *P. aeruginosa* and to advance targeted therapeutic plans to fight multidrug-resistant infections efficiently.

CONCLUSIONS

In conclusion, the study underscores the urgent need for multifaceted approaches to address *P. aeruginosa* infections in burn patients, emphasizing the importance of judicious antibiotic use, infection control measures, and ongoing surveillance to combat antibiotic resistance and reduce morbidity and mortality associated with these infections.

Conclusion

Despite having a high emotional intelligence, ambulance workers struggle with considerable stress and fatigue as a result of their busy schedules and poor work-life balance. Although there are links between these parameters, more study is still required. It is still essential for their performance and

Ahmad et al - 2026

3007-2387

3007-2379

DOI: <http://doi.org/10.5281/zenodo.20508991>

general well-being to prioritize sleep, breaks, and healthier work habits. In order to support the well-being and maximize the performance of ambulance staff, this study highlights the obstacles they experience and highlights the necessity for interventions that promote healthy work practices and work-life balance.

Conflict of Interest:

No potential conflict of interest relevant to this article was reported.

REFERENCES

- 1.Chen L, Zou Y, She P, Wu Y. Composition, function, and regulation of T6SS in *Pseudomonas aeruginosa*. *Microbiological research*. 2015;172:19-25.
- 2.Lau GW, Hassett DJ, Ran H, Kong F. The role of pyocyanin in *Pseudomonas aeruginosa* infection. *Trends in molecular medicine*. 2004;10(12):599-606.
- 3.Crone S, Vives-Flórez M, Kvich L, Saunders AM, Malone M, Nicolaisen MH, et al. The environmental occurrence of *Pseudomonas aeruginosa*. *Apmis*. 2020;128(3):220-31.
- 4.Laborda P, Martínez JL, Hernando-Amado S. Evolution of habitat-dependent antibiotic resistance in *Pseudomonas aeruginosa*. *Microbiology Spectrum*. 2022;10(4):e00247-22.
- 5.Michel-Briand Y, Baysse C. The pyocins of *Pseudomonas aeruginosa*. *Biochimie*. 2002;84(5-6):499-510.
- 6.Wu W, Jin Y, Bai F, Jin S. *Pseudomonas aeruginosa*. *Molecular medical microbiology*: Elsevier; 2015. p. 753-67.
- 7.Bassetti M, Vena A, Croxatto A, Righi E, Guery B. How to manage *Pseudomonas aeruginosa* infections. *Drugs in context*. 2018;7.
- 8.Kerr KG, Snelling AM. *Pseudomonas aeruginosa*: a formidable and ever-present adversary. *Journal of Hospital Infection*. 2009;73(4):338-44.

9. Zhapouni A, Farshad S, Alborzi A. Pseudomonas aeruginosa: burn infection, treatment and antibacterial resistance. 2009.
10. Mahar P, Padiglione AA, Cleland H, Paul E, Hinrichs M, Wasiak J. Pseudomonas aeruginosa bacteraemia in burns patients: risk factors and outcomes. Burns. 2010;36(8):1228-33.
11. Tamma PD, Simner PJ. Phenotypic detection of carbapenemase-producing organisms from clinical isolates. Journal of clinical microbiology. 2018;56(11):10.1128/jcm. 01140-18.
12. Krell T, Matilla MA. Pseudomonas aeruginosa. Trends in microbiology. 2024;32(2):216-8.
13. Biswal I, Arora BS, Kasana D. Incidence of multidrug resistant Pseudomonas aeruginosa isolated from burn patients and environment of teaching institution. Journal of clinical and diagnostic research: JCDR. 2014;8(5):DC26.
14. Bhatt P, Rathi KR, Hazra S, Sharma A, Shete V. Prevalence of multidrug resistant Pseudomonas aeruginosa infection in burn patients at a tertiary care centre. Indian Journal of Burns. 2015;23(1):56-9.
15. Coetzee E, Rode H, Kahn D. Pseudomonas aeruginosa burn wound infection in a dedicated paediatric burns unit. South African Journal of Surgery. 2013;51(2):50-3.
16. Kunwar A, Shrestha P, Shrestha S, Thapa S, Shrestha S, Amatya NM. Detection of biofilm formation among Pseudomonas aeruginosa isolated from burn patients. Burns Open. 2021;5(3):125-9.
17. Arslan E, Dalay C, Yavuz M, Göcenler L, Acartürk S. Gram-negative bacterial surveillance in burn patients. Proteus. 1999;95:53.
18. Naqvi ZA, Hashmi K, Rizwan QM, Kharal SA. Multidrug resistant Pseudomonas aeruginosa: a nosocomial infection threat in burn patients. Pakistan Journal of Pharmacology. 2005;22(2):9-15.
19. Bhatt S, Weiss D, Cameron E, Bisanzio D, Mappin B, Dalrymple U, et al. The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015. Nature. 2015;526(7572):207-11.

Ahmad et al - 2026

3007-2387

3007-2379

DOI: <http://doi.org/10.5281/zenodo.20508991>

-
20. Ekrami A, Kalantar E. Bacterial infections in burn patients at a burn hospital in Iran. Indian Journal of Medical Research. 2007;126(6):541-4.
21. MOAZAMI GS, Eftekhari F. Assessment of carbapenem susceptibility and multidrug-resistance in *Pseudomonas aeruginosa* burn isolates in Tehran. 2013.
22. Sadari H, Lotfalipour H, Owlia P, Salimi H. Detection of metallo- β -lactamase producing *Pseudomonas aeruginosa* isolated from burn patients in Tehran, Iran. Laboratory Medicine. 2010;41(10):609-12.